|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Sanofi
|
|
gptkbp:acquisition
|
gptkb:Amgen
|
|
gptkbp:awards
|
gptkb:Biotech_Breakthrough_Award
Best Places to Work
Innovative Company Award
|
|
gptkbp:clinical_trial
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaborations
|
academic institutions
research organizations
|
|
gptkbp:community_involvement
|
gptkb:Educational_Institution
volunteer work
healthcare initiatives
charitable donations
|
|
gptkbp:focus
|
protein therapeutics
|
|
gptkbp:founded
|
gptkb:2004
|
|
gptkbp:founder
|
gptkb:M._A._(Marty)_W._A._van_der_Velden
|
|
gptkbp:headquarters
|
gptkb:San_Carlos,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amunix Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:investment
|
gptkb:Kleiner_Perkins
gptkb:Sofinnova_Ventures
gptkb:Canaan_Partners
gptkb:MPM_Capital
gptkb:Orbi_Med_Advisors
|
|
gptkbp:key_people
|
gptkb:Peter_A._G._H._van_der_Velden
|
|
gptkbp:mission
|
develop innovative therapies
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:products
|
gptkb:AMX-0035
gptkb:AMX-196
gptkb:AMX-818
|
|
gptkbp:receives_funding_from
|
gptkb:Company
|
|
gptkbp:regulatory_compliance
|
FDA approval
EMA approval
|
|
gptkbp:research
|
autoimmune diseases
infectious diseases
cancer therapies
|
|
gptkbp:services
|
clinical trials
drug development
|
|
gptkbp:sustainability_initiatives
|
sustainable practices
energy efficiency
green initiatives
environmental responsibility
|
|
gptkbp:technology
|
XTEN technology
|
|
gptkbp:type
|
private company
|
|
gptkbp:values
|
gptkb:collaboration
innovation
integrity
excellence
|
|
gptkbp:vision
|
transform patient care
|
|
gptkbp:website
|
www.amunix.com
|